Morgan Lamberti's questions to Krystal Biotech Inc (KRYS) leadership • Q2 2025
Question
Morgan Lamberti from Goldman Sachs asked if the Japan launch would require an initial healthcare practitioner visit and requested details on the fifth patient dosed in the AATD study.
Answer
Chairman & CEO Krish Krishnan confirmed the Japan launch process is similar to Europe, requiring an initial physician visit. President of R&D Suma Krishnan noted that across all three bronchoscopy patients, they saw robust expression in biopsy samples, and in two of those patients, they were able to measure AAT in the lavage and see a reduction in neutrophil elastase.